

Benefits of second-look laparoscopy in the management of pelvic inflammatory disease

Anne Sophie Gremeau, Anais Girard, Celine Lambert, Pauline Chauvet, Nicolas Bourdel, Michel Canis, Jean Luc Pouly

► To cite this version:

Anne Sophie Gremeau, Anais Girard, Celine Lambert, Pauline Chauvet, Nicolas Bourdel, et al.. Benefits of second-look laparoscopy in the management of pelvic inflammatory disease. Journal of Gynecology Obstetrics and Human Reproduction, 2019, 48, pp.413 - 417. 10.1016/j.jogoh.2019.03.020 . hal-03484954

HAL Id: hal-03484954 https://hal.science/hal-03484954

Submitted on 20 Dec 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

Benefits of second-look laparoscopy in the management of pelvic inflammatory disease

AUTHORS GREMEAU Anne Sophie, MD Department of Gynecology, University Hospital, Clermont-Ferrand, France

GIRARD Anais, MD, Department of Gynecology, University Hospital, Clermont-Ferrand, France

LAMBERT Celine Biostatistics Unit (DRCI), University Hospital, Clermont-Ferrand, France

CHAUVET Pauline, MD Department of Gynecology, University Hospital, Clermont-Ferrand, France

BOURDEL Nicolas, PHD Department of Gynecology, University Hospital, Clermont-Ferrand, France

CANIS Michel, PHD Department of Gynecology, University Hospital, Clermont-Ferrand, France

POULY Jean Luc, PHD Department of Gynecology, University Hospital, Clermont-Ferrand, France

Correponding author :

GREMEAU Anne Sophie, MD asgremeau@chu-clermontferrand.fr CHU Clermont-Ferrand, Department of gynecology 1 place Lucie et Raymond AUBRAC, 63100 Clermont Ferrand Cedex 1, France +0033 473755042

2 INTRODUCTION

3 Pelvic inflammatory disease (PID) involves deep and severe visceral infections due 4 to bacteria from the endometrium attaining the fallopian tubes following sexually transmitted 5 infection (STI), an endo-uterine maneuver or due to neighboring infection. (1). In France, 6 200,000 new cases of PID are recorded per year, with 55% of patients aged under 25. These 7 young women are of childbearing age and have a high risk of complications such as chronic 8 pelvic pain, recurrence, ectopic pregnancy and infertility sequelae (2). Success of PID 9 treatment may not lead to anatomical ad-integrum restitution, and only intra-uterine 10 pregnancy being the best indicator of complete healing.

11

12 Treatment involves antibiotics at the acute phase and surgical management may be necessary when imaging reveal tubo-ovarian abscess, in cases of poor clinical tolerance, 13 14 resistance to medical treatment or unconfirmed diagnosis as specified in French (3,4), 15 European (5) and American (6) recommendations. Surgical management in the acute phase is 16 drainage of the abcess and should be done by laparoscopy or by puncture under vaginal 17 guidance. Using surgical classification, initial management by laparoscopy, makes it possible 18 to determine 3 stages of salpingitis (7) At stage 1 (catarrhal) tubes reveal congestion and hyperemia, stage 2 (parenchymatous) is characterised by increased inflammation levels, and 19 20 stage 3 (severe salpingitis) by the presence a tubo-ovarian abscess. Second-look laparascopy 21 (SLL) are only reserved for cases of infertility or chronic pelvic pain.

22

These recommendations favoring medical treatment are based on conclusions from the PEACH study (8,9) which reported that following medical treatment only, 57% of patients conceived and 42% delivered. These encouraging results brought about changes in practice and notably a considerably reduced use of first surgery and of SLL, even though the study only included patients with moderate PID and excluded "tubo-ovarian abscess and surgical
abdomens". Furthermore the study reported unacceptably high results for infertility (19%) and
subsequent pelvic pain (42%) for patients treated for moderate levels of PID. A comparison
of these results with those obtained from systematic surgical management and particularly for
acute cases, remains to be carried out. Lastly, no further treatment was proposed to allow
evaluation of fertility or reduce risk of complications.

33

Previously both Bouedec et al (10) and Raiga et al (11) had presented results in favor SLL for assessment and restoring of patient fertility. Notably the possibility of obtaining a prognosis concerning fertility, based on the Mage score (grade 1 to 4) obtained from tubal evaluation (12) and an adhesion score using the American Fertility Society classification (AFS) (13). These scores are described in table 1. This present study aims to evaluate the results and benefits of SLL in cases of PID and to evaluate risk factors that lead to severe complications concerning fertility and which indicate the need for SLL.

41

42 Materials and Methods

43 This unicentric retrospective study was carried out at Clermont-Ferrand University Hospital Center over a 5-year period from January 1, 2010 to December 31, 2014. Inclusion 44 45 criteria concerned all patients who had undergone SLL due to PID initially treated either 46 medically or surgically. A total of 188 patients had received treatment for PID and benefited 47 from a hospital stay (outpatients were not included). Of these, 96 were excluded because they didn't have SLL (age> 43 years, associated endometriosis, immediate management for 48 49 assisted reproductive techniques (ART) and patient refusal) and 16 had SLL but incomplete data (missing data or more than 10 years between initial PID and SLL). A total of 76 patients 50 51 were finally included as described in the Flow chart (table 2).

Extensive data collection was carried out to include patient characteristics, clinical and para-clinical characteristics of salpingitis, initial medical and surgical management data, indications and SLL details, and information concerning long-term follow-up notably patient fertility. Two scores relating to fertility were obtained for each surgical intervention: the Mage score (grade 1 to 4) for tubal assessment and the AFS classification concerning adhesions (score 0 to 3). AFS scores 0 and 1 were included in the analyses and so provided increased statistical power.

60

Statistical analysis was performed using Stata software (version 13, StataCorp, 61 College Station, Texas, USA). All tests were two-sided, with a Type I error set at 0.05. 62 Categorical parameters were expressed as frequencies and associated percentages, and 63 64 continuous data as mean ± standard deviation or as median [interquartile range], according to 65 statistical distribution. Categorical variables were compared between independent groups 66 (PID stage 1 or 2 vs. PID stage 3, and medical vs. surgical initial management) using the chi-67 square test or the Fisher exact test. Quantitative data were compared between groups with the Student t test or with the Mann-Whitney test, as appropriate. The Gaussian distribution was 68 verified by the Shapiro-Wilk test and homoscedasticity by the Fisher-Snedecor test. 69 70 Furthermore, a multivariable ordinal logistic regression was used to predict AFS stage, using 71 covariates according to univariate results and clinical relevance: age, tubal surgery and PID 72 stage (1 or 2 vs. 3). Because of the small sample (n=57), few variables were included in the 73 model. The results were expressed as odds ratio (OR) and 95% confidence interval.

74

75 **RESULTS**

Our study included 76 patients who underwent SLL post-PID, with an average of 15 76 77 per years. General patient characteristics and details of the initial infection episode are summarized in Table 3. When chlamydiae trachomatis has been requested IgG serology was 78 positive in 72,9%, and PCR in 39,5%. Other germs were streptococcus, E coli, Neisseiria 79 gonorrhae ans staphyloccoccus aureus. Antibiotic therapy was administered in 100% of 80 cases. Before the french recommandation differents bi ou tri-antibiothérapy were used 81 (amoxicillin and clavulanic acid, levofloxacin, metronidazol and/or ofloxacin). Since 2012 82 83 association of Metronidazol and ofloxacin were the reference. Initial surgical management was performed in 57 (75%) patients, the indications were the presence of an abscess 84 confirmed by imaging, uncertain diagnosis and unfavorable clinical evolution in (26.3%). 85 During initial surgery, 57.9% of patients were found to have stage 3 salpingitis. Procedure 86 during initial surgery was adhesiolysis in 93%, salpingectomy in 5.3%, abcess drainage 87 88 including salpingotomy in 43.9%. Dye tests werent't performed during initial surgery.

89

90 Indication of the SLL were pelvic pain (21.1%), hydrosalpinx (18.4%) and others 91 were offered routinely (60.5%). During SLL, 78.9% of patients underwent adhesiolysis and 92 42.1% tube-related treatment. (19,7% of salpingectomy and 22,4% of neostomy or 93 fimbrioplasty. The median time between initial surgery and SLL was 3.5 months [3; 5]. An 94 adhesion score was recorded for all patients and the Mage score obtained for 72 patients. 63 95 patients received long-term follow-up and were contacted by phone, of whom 30 patients 96 (34%) expressed a desire to conceive. We had 23 pregnancies and outcomes were as follows: 16 live births (69.6%), 2 ectopic pregnancy (8.7%), 2 early miscarriage (8.7%) and 3 97 98 abortions (13%). Only 5 patients benefited from ART, and two pregnancies were due to IVF. 99 The infertility rate was 23.3%.

102 Subgroup analyses allowed comparison of SLL characteristics in relation to the PID 103 stage (Table 4) Due to low patient numbers, those with an initial salpingitis stage of 1 and 2 104 were combined to form a single group of 24 patients, compared to 33 stage 3 patients. At the 105 initial laparoscopy, results revealed 72.7% of severe adhesions at stage 3 as compared to 25% 106 for stages 1 and 2 (p = 0.001). During SLL, more patients in this group received a high 107 adhesions score and a Mage score of 4 (27.3% vs 0%, p = 0.001). Multivariate analysis 108 revealed that stage 3 patients are 8.2 times more likely to have higher adhesion levels than 109 stage 1 or 2 patients (OR [95% CI] = 8.2 [2.2; 30.5], p = 0.02).

110

111 Finally, analysis of the relationship between fertility and Mage and adherence scores 112 at SLL was performed by comparing patients who conceived after surgery with those who did 113 not. A total of 30 patients with a childbearing project were selected and included 23 who 114 conceived. Results obtained during SLL allowed the authors to establish a relationship 115 between the pregnancies obtained, their characteristics and fertility scores. Mage scores of 1 116 or 2 were found to be associated with a higher pregnancy and birth rate), although this result 117 was not significant. Mage score of 4 was significantly associated with a higher ectopic pregnancy rate. These results are shown in Table 5. 118

119

120 **DISCUSSION**

The Kreisel study conducted in the US found a 4.4% prevalence of PID in sexually active women, this report highlight the magnitude of this public health issue which impacts young women of childbearing age (14). As explained in the introduction, since 2012 as a result of the PEACH study (9), guidelines no longer recommend systematic surgical management, and medical treatment by antibiotics is the first-line therapy (3-6). But, the 126 conclusions were uniquely based on cases of moderate PID for which complication rates were
127 still high i.e. 19% infertility and 42% chronic pelvic pain. At least, first line antibiotherapy
128 have never shown their efficacity on fertility after PID especially in severe forms (10).

129 Studies investigating initial surgical management in PID, include the Chayachinda 130 cohort conducted from 2004 to 2011, which reported a low surgical rate of 12.8% for patients 131 with tubo-ovarian abscess (TOA) (15). Kontoravdis et al, reported a 22.8% rate of surgery for 132 patients with acute pain linked to salpingitis (16). In our study a higher rate of patients 133 underwent primary laparoscopy (75%), of whom more than half had TOA, our results shows 134 that we probably made two much initial surgery, but the evaluation of the SLL, confirmed that 135 severe PID are more at risk of potential complications like adhesions and tubal infertility and ectopic pregnancies. This is confirmed by the recent French recommendation which support 136 137 the drainage of tubo-ovarian abcess. This drainage should be realized by vaginal puncture 138 under ultrasound guidance or by laparoscopy, as quickly as possible. Our results, in 139 agreement with this guidelines showed that initial surgery shouldn't by systematic except in 140 severe form with TOA (3,4).

141 Up to date, in cases of abscess > 3 cm, present guidelines advocate drainage by 142 transvaginal route, due to the feasibility and reproducibility of this technique. Granberg et al, 143 in a review of the literature reported a success rate in 77 -100% of patients (17) and the 144 French Vermersch study a success rate of 94% (18). Gielland, reported complete healing from 145 infection in 93.4% of patients (19). In a second study, published in 2012, 52.8% of patients 146 who underwent draining and wished to become pregnant, conceived (20). But patients "who 147 had undergone surgery (after drainage) that made future pregnancy not recommandable" were 148 excluded. Only 38 "good cases" were included and finally only 22 give birth (52%), So if 149 vaginal drainage, is efficient on the treatment of the acute phase of PID, we have very poor

151

data about fertility. Moreover, no study to our knowledge has compared efficacy in terms of clinical efficiency and fertility of vaginal vs laparoscopic drainage, data are still missing.

152 Infertility rates following PID can be high, such as in the USA where rates may vary 153 from 21.3% - 55.6% (9). In our study we found a 37,5% infertility rate, with only 15 out of 24 154 women desiring to conceive, who delivered. Assessment of fertility in post-PID patients is 155 frequently difficult, requiring long-term follow-up for collection of data on pregnancy and 156 acute episode outcomes. SLL therefore provides a key opportunity to collect validated fertility 157 scores, specifically MAGE and AFS adhesion scores as previously described. Accordingly 158 Mage et al (1987) highlighted the relationship between the salpingitis stage, second-look 159 laparoscopy and fertility prognosis, and reported a pregnancy rate that ranged from 58.3% for 160 stage I to 0% for stage IV (12). These results were confirmed by following studies as Le bouedec (1991), Raiga (1996) Gerber et al (1996) who performed control laparoscopies and 161 found high rates of adhesions and tubal occlusion (10,11,21). In a recent retrospective study 162 163 Chayachinda et al. (2017), used multivariate analysis to show that the presence of a tubo-164 ovarian abscess is a negative predictor of delivery rate (15). Finally, Audebert et al (2014) 165 reported on a more than 10-year follow-up of 434 patients who underwent neosalpingostomy, 166 and consequently advised performing tubal repair in patients selected on the basis of adhesion 167 stage and tubal score. (22). All these results confirmed the interest of a SLL after TOA, and 168 the treatment of the adhesions or the tubal defects. But it's also highlight that no studies and 169 no data are available about fertility post vaginal drainage of TOA, because all SLL were made 170 following laparoscopic intial treatment.

Our study revealed an association between initial infection, secondary adhesions, Mage score and patient fertility. Thus patients with stage 3 PID are 8 times more likely to present with a high level of adhesions than stage 1 or 2 patients (OR [95% CI] = 8.2 [2.2; 30.5], p = 0.02). Mage scores of 1 or 2 are associated with higher pregnancy and delivery

rates than Mage of 3 or 4 (p = ns), and Mage score of 4 are associated with highly ectopic 175 pregnancies (p = 0.03). These figures correlate with the severity of the initial infection. SLL 176 177 should therefore be recommended in women who have presented with tubo-ovarian abscess. 178 Some theories estimates that's more the initial infection is severe, more the initial treatment of 179 the tube and its repair in case of damage is quick, more the benefits on the fertility is 180 important (23,24). We also knows that the infected tubes are also more susceptible to 181 blockage, which if unresolved may lead to hydrosalpinx, a condition resulting in reduced 182 results in IVF as demonstrated by Strandell (25). This provides further evidence in support of 183 carrying out second look laparoscopy in patients wishing to conceive; usually performed by 184 infertility surgeons, experienced in tubal surgery.

185 The main limitation of our study concerns its retrospective nature and corresponding issues linked to data collection and reliability. But, our study is the first since the publishing 186 187 of CNGOF guidelines, to report on fertility following SLL and thus highlight patient groups 188 susceptible to benefit from this technique. For patients, the outcomes of upmost importance is 189 giving birth to a healthy child. Long-term follow-up data is also necessary for assessment of risk of recurrences and pelvic pain. A prospective randomized study about SLL after tubo-190 191 ovarian abcess is actually in progress in our center (ClinicalTrials.gov Identifier: 192 NCT03166982).

193

194 CONCLUSION

Over recent years there has been a sharp increase in the incidence of PID in women of childbearing age. Recents guidelines about PID endorse the use of dual-antibiotic therapy, reserving first-line surgery for complicated severe cases and second look laparoscopy (SLL) for selected patients with pelvic pain. Our study, revealed an association between PID initial stages, adhesions, tube- related procedures and patient fertility. While SLL was shown to have

- 200 little impact on the preservation of fertility in cases of mild to moderate PID, our results find
- an interest of recommending SLL in women desirous pregnancy and who had a tubo-ovarian
- abscess at the initial stage. Prospective studies should be done to confirm these results.
- 203

| 205 | Re | ferences |
|-----|-----|---|
| 205 | I | |
| 200 | 1. | Mitchell C, Prabhu M. Pelvic inflammatory disease: current concepts in pathogenesis, |
| 208 | 1 | diagnosis and treatment. Infect Dis Clin North Am. 2013 Dec;27(4):793-809. |
| 209 | 2- | InVS. Bulletins des reseaux de surveillance des ISTs (internet). 2015. Available from : |
| 210 | 4- | http://invs.santepubliquefrance.fr |
| 210 | 3_ | Graesslin O. Pelvic inflammatory diseases: guidelines for clinical practice - method |
| 212 | 0 | and organization.J Gynecol Obstet Biol Reprod (Paris). 2012 Dec;41(8):833-4 |
| 213 | 4- | Brun JL, Graesslin O, Fauconnier A, Verdon R, Agostini A, Bourret et al; Collège |
| 214 | • | National des Gynécologues Obstétriciens Français Updated French guidelines for |
| 215 | | diagnosis and management of pelvic inflammatory disease. Int J Gynaecol Obstet. |
| 216 | | 2016 Aug;134(2):121-5. |
| 217 | 5- | Ross J, Judlin P, Jensen J; International Union against sexually transmitted infections. |
| 218 | e | 2012 European guideline for the management of pelvic inflammatory disease. Int J |
| 219 | | STD AIDS. 2014 Jan;25(1):1-7. |
| 220 | 6- | Haulk L. CDC Releases 2015 guidelines on the treatment of sexually transmitted |
| 221 | | disease. Am Fam Physician, 2016 Jan 2015;93(2):144-54. |
| 222 | 7- | |
| 223 | | édition 2015;64-71. |
| 224 | 8- | Trent M, Bass D, Ness RB, Haggerty C. Recurrent PID, subsequent STI, and |
| 225 | | reproductive health outcomes: findings from the PID evaluation and clinical health |
| 226 | | (PEACH) study. Sex Transm Dis. 2011 Sep;38(9):879-81. |
| 227 | 9- | Ness RB, Soper DE, Holley RL, Peipert J, Randall H, Sweet RL, et al. Effectiveness |
| 228 | | of inpatient and outpatient treatment strategies for women with pelvic inflammatory |
| 229 | | disease: results from the Pelvic Inflammatory Disease Evaluation and Clinical Health |
| 230 | | (PEACH) Randomized Trial. Am J Obstet Gynecol. 2002 May;186(5):929-37. |
| 231 | 10- | - Le Bouëdec G, Pouly JL, Canis M, Wattiez A, Abbas B, Mage G, Bruhat MA Acute |
| 232 | | salpingitis. Celioscopy before and after treatment: 110 cases] J Gynecol Obstet Biol |
| 233 | | Reprod (Paris). 1991;20(5):680-4. |
| 234 | 11 | - Raiga J, Canis M, Le Bouëdec G, Glowaczower E, Pouly JL, Mage G, Bruhat MA. |
| 235 | | Laparoscopic management of adnexal abscesses: consequences for fertility. Fertil |
| 236 | | Steril. 1996 Nov;66(5):712-7. |
| 237 | 12 | - Mage G, Pouly JL, de Jolinière JB, Chabrand S, Riouallon A, Bruhat MA. A |
| 238 | | preoperative classification to predict the intrauterine and ectopic pregnancy rates after |
| 239 | | distal tubal microsurgery. Fertil Steril. 1986 Nov;46(5):807-10. |
| 240 | 13 | - The American Fertility Society classifications of adnexal adhesions, distal tubal |
| 241 | | occlusion, tubal occlusion secondary to tubal ligation, tubal pregnancies, müllerian |
| 242 | | anomalies and intrauterine adhesions. Fertil Steril. 1988 Jun;49(6):944-55. |
| 243 | 14 | - Kreisel K, Torrone E, Bernstein K, Hong J, Gorwitz R. Prevalence of Pelvic |
| 244 | | Inflammatory Disease in Sexually Experienced Women of Reproductive Age - United |
| 245 | | States, 2013-2014. MMWR Morb Mortal Wkly Rep. 2017 Jan 27;66(3):80-83. |

- 246 15- Chayachinda C, Rekhawasin T. Reproductive outcomes of patients being hospitalised
 247 with pelvic inflammatory disease. J Obstet Gynaecol. 2017 Feb; 37 (2):228-232.
- 248 16- Kontoravdis A, Chryssikopoulos A, Hassiakos D, Liapis A, Zourlas PA. The diagnostic value of laparoscopy in 2365 patients with acute and chronic pelvic pain.
 250 Int J Gynaecol Obstet. 1996 Mar;52(3):243-8.
- 251 17- Granberg S, Gjelland K, Ekerhovd E. The management of pelvic abscess. Best Pract
 252 Res Clin Obstet Gynaecol 2009; 23 (5):667–78.
- 18- Vermersch C, Dessein R, Lucot JP, Rubod C, Cosson M, Giraudet G. Tubo-ovarian
 abscesses treatment: Faisability and results of trans-vaginal ultrasound-guided
 aspiration. J Gynecol Obstet Biol Reprod 2016 Mar;45(3):243-8
- **19-** Gjelland K, Ekerhovd E, Granberg S. Transvaginal ultrasound-guided aspiration for treatment of tubo-ovarian abscess: a study of 302 cases. Am J Obstet Gynecol. 2005
 Oct;193(4):1323-30.
- 259 20- Gjelland K, Granberg S, Kiserud T, Wentzel-Larsen T, Ekerhovd E. Pregnancies
 260 following ultrasound-guided drainage of tubo-ovarian abscess. Fertil Steril. 2012
 261 Jul;98(1):136-40.
 - **21-** Gerber B, Krause A. A study of second-look laparoscopy after acute salpingitis. Arch Gynecol Obstet. 1996; 258 (4):193-200.
- 264 22- Audebert A, Pouly JL, Bonifacie B, Yazbeck C. Laparoscopic surgery for distal tubal
 265 occlusions: lessons learned from a historical series of 434 cases. Fertil Steril. 2014
 266 Oct;102(4):1203-8.
 - 23- Jacobson L, Weström L. Objectivized diagnosis of acute pelvic inflammatory disease. Diagnostic and prognostic value of routine laparoscopy. Am J Obstet Gynecol. 1969 Dec 1;105(7):1088-98.
 - **24-** Weström L. Incidence, prevalence, and trends of acute pelvic inflammatory disease and its consequences in industrialized countries. Am J Obstet Gynecol. 1980 Dec 1;138(7 Pt 2):880-92.
 - **25-** Strandell A. The influence of hydrosalpinx on IVF and embryo transfer. A review. Human Reprod Update. 2000 Jul-Aug;6(4):387-95
- 275 276

267

268

269 270

271 272

273

274

Table 1 : AFS Adhesion score and MAGE score

<u>Mage Score</u>

| Score | 0 | 2 | 5 | 10 |
|--------------|--------------------------|----------|------------------|-------------------------|
| Permeability | | Phimosis | Hydro-salpinx | |
| Tubal mucosa | Mucosal folds maintained | | Folds diminished | No folds ou synechia |
| Tubal wall | Normal | | Thin | Thick |


Stage 1 (2-5) ; stage 2 (6-10) ; stage 3 (11-15) ; stage 4 (>15)

AFS adhesion Score

| | ADHESIONS | | < 1/3 Enclosure | 1/3-2/3 | >2/3 Enclosure |
|-------|-----------|-------|-----------------|-----------|----------------|
| | | | | Enclosure | |
| OVARY | R | Filmy | 1 | 2 | 4 |
| | | Dense | 4 | 8 | 16 |
| | L | Filmy | 1 | 2 | 4 |
| | | Dense | 4 | 8 | 16 |
| TUBE | R | Filmy | 1 | 2 | 4 |
| | | Dense | 4* | 8* | 16 |
| | L | Filmy | 1 | 2 | 4 |
| | | Dense | 4* | 8* | 16 |

*If the fimbria end of the fallopian tube is completely enclosed, change the point assignment to 16 **Stage I : no adhesions, Stage II : mild adhesions (1-6) ; stage III : moderate adhesions (7-15) ; stage IV : severe adhesions (>15)**

Table 2 : Flow chart of the study



| | Total (n=76) |
|--|-----------------------------------|
| Age (years) | 27.6 ± 8.5 |
| Age >37 years | 14 (18.4) |
| Medical history | 26(240) |
| Abortion | 26 (34.2) |
| Sexually transmitted infections | 7 (9.2) |
| Abdominal-pelvic surgery | 26 (34.2) |
| Intrauterine device | 22 (28.9) |
| Smoking | 43/64 (67.2) |
| Symptoms | 76 (100.0 |
| Pelvic pain | 21 (27.6 |
| Defense | 40 (52.6) |
| Leucorrhoea | 31 (40.8 |
| Fever >38°C | 2 (2.6 |
| Severe sepsis | 2 (2.0 |
| Paraclinical tests | 9/72 (12.5 |
| Normal echography | 34/72 (47.2 |
| Abscess | 43.5 ± 14.3 |
| Size of abscess (mm) | 13.3 [9.4; 17.8 |
| White blood cells (g/l) | 92.6 [43.9; 171.0 |
| C-reactive protein (mg/l) | 35/48 (72.9 |
| Chlamydia serology IgG + | 15/38 (39.5 |
| Chlamydia PCR positive | 15/58 (59.5 |
| Initial treatment Antibiotic treatment | 76 (100.0 |
| Surgical treatment | 57 (75.0 |
| Adhesiolysis | 53/57 (93 |
| Salpingectomy | 3/57 (5.3 |
| Drainage | 25/57 (43,9 |
| PID stage | 20101 (10,5 |
| 1 ID stage | 6/57 (10.5 |
| 2 | 18/57 (31.6 |
| 3 | 33/57 (57.9 |
| | 55157 (51.9 |
| Second-look laparoscopy Indication | |
| Systematic | 46 (60.5 |
| Pelvic pain | 16 (21.1 |
| 1 | 14 (18.4 |
| Imagery Length of surgery (minutes) | 37 [30; 51 |
| | |
| Adhesions score (AFS) | 18 (23.7 |
| Stage I-II (none or small) | 25 (32.9 |
| Stage III (moderate) | 33 (43.4 |
| Perihepatitis (Fitz Hugh Curtis) Stage IV (severe) | 8 (10.5 |
| Tubal score (MAGE) | |
| Stage 1 | 52/72 (72.2 |
| Stage 2 | 6/72 (8.3 |
| Stage 3 | 5/72 (7.0 |
| Stage 4 | 9/72 (12.5 |
| - | |
| Adhesiolysis Salaingeetamy | 60 (78.9 15 (10 7 |
| Salpingectomy | 15 (19.7 |
| Neostomy or fimbrioplasty | 17 (22.4 an + standard_deviati |

Table 3: Patient and PID characteristics, treatment and second-look laparoscopy

Data are presented as frequencies (associated percentage), as mean ± standard deviation, or as median [interquartile range].

| | Stage 1 or 2 (n=24) | Stage 3 (n=33) | p-value |
|--|--|--|----------------------|
| Paraclinical tests | | | |
| Normal echography | 2/21 (9.5) | 1/32 (3.1) | 0.34 |
| Abscess | 6/21 (28.6) | 25/32 (78.1) | <0.001 |
| White blood cells (g/l) | 10.2 [7.9; 15.3] | 15.6 [12.9; 19.2] | 0.004 |
| C-reactive protein (mg/l) | 90.2 [39.8; 132.0] | 91.7 [37.0; 188.0] | 0.42 |
| Chlamydia serology IgG | 11/14 (78.6) | 16/26 (61.5) | 0.32 |
| PCR positive chlamydia | 8/13 (61.5) | 3/14 (21.4) | 0.03 |
| Initial surgery | | | |
| Severe adhesions (stage IV AFS) | 6 (25.0) | 24 (72.7) | <0.001 |
| Salpingectomy | 0 (0) | 3 (9.1) | 0.26 |
| Abscess drainage | 3 (12.5) | 22 (66.7) | <0.001 |
| Second-look laparoscopy | | | |
| Adhesions score (AFS) Stage I-II (none or small) Stage III (moderate) Stage IV (severe) | 6 (25.0) 12 (50.0) 6 (25.0) | 4 (12.1) 8 (24.3) 21 (63.6) | 0.02 |
| Tubal score (MAGE) Stage 1 Stage 2 Stage 3 Stage 4 | 21/23 (91.3) 0/23 (0.0) 2/23 (8.7) 0/23 (0.0) | 16 (48.5) 6 (18.2) 2 (6.0) 9 (27.3) | <0.001 |
| Adhesiolysis Salpingectomy Neostomy or fimbrioplasty | 20 (83.3) 1 (4.2) 6 (25) | 29 (87.9) 10 (30.3) 10 (30.3) | 0.71 0.02 0.66 |

<u>Table 4: Second look laparoscopy (SLL) characteristics depending on</u> <u>initial PID stage(n = 57 patients)</u>

Data are presented as frequencies (associated percentage), as mean ± standard deviation, or as median [interquartile range].

| | n | Pregnancies | Ectopic pregnancies | Deliveries |
|----------------------------|----|--------------|------------------------|--------------|
| Adhesions score (AFS) | | | | |
| Stage I-II (none or small) | 7 | 5/7 (71.4) | 0/7 (0.0) | 4/7 (57.1) |
| Stage III (moderate) | 9 | 8/9 (88.9) | 0/9 (0.0) | 7/9 (77.8) |
| Stage IV (severe) | 14 | 10/14 (71.4) | 2/14 (14.3) | 5/14 (35.7) |
| p-value | | 0.64 | 0.49 | 0.13 |
| Tubal score (MAGE) | | | | |
| Stage 1 | 24 | 19/24 (79.2) | 0/24 (0.0) | 15/24 (62.5) |
| Stage 2 | 4 | 2/4 (50.0) | 1/4 (25.0) | 1/4 (25.0) |
| Stage 3 | 0 | Ó | Ó | Ó |
| Stage 4 | 2 | 2/2 (100.0) | 1/2 (50.0) | 0/2 (0.0) |
| p-value | | 0.27 | 0.03 | 0.14 |

Table 5: Fertility according to tubal and adhesion score during second-look laparoscopy (n=30)

Data are presented as frequencies (associated percentage).